Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (15208)	2/17/1998 5:52:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FUGAZI, I don't think that there is a consensus on LGND's trading range. Some expect it to be trading below $10 soon while others are looking at at $25 target price. LGND has a very broad program which should pay rich dividends for the patient long term investor. Since one of the reports I cited was the most comprehensive I've seen on LGND, while the other just came out at the end of 1997, it's worth looking at the predictions. I found it interesting that the projections for 2003 were very close, as are the predictions for 1999. There are clearly some traders on this board, but many posters and more lurkers (based on the E-Mail that I have received) are long term investors in LGND and are interested in what analysts say about its long term prospects. Short term, some recommend revisiting LGND (and Biotechs) in August. Base on recent price and volume increases, it seems that many are interested in its action during the "off season". In case you missed it, LGND did just come out with three pieces of good news and moved up significantly. IR suggests much more is to come. Although some consider this the "off season", some of their predictions are wrong, at best.

To: Hippieslayer who wrote (15208)	2/17/1998 5:58:00 PM
From: Andreas Helke	Respond to of 32384

If we take a look at the not so distant future we will soon have a biotech with positive earnings. Those go with a marketcap of about 1 billion dollar depending on the promise of the future pipeline and perceived risks for their current cash cows. I would say if we get good phase II data for breast cancer that together with many other projects of Ligand and its pharma partners is probably good for another billion of market cap. This would lead to a halfways realistic target of $50 per share within the next two years without resorting to highly unreliable future earnings estimates. Of course it depends on the yet unknown success of Ligands compounds in major human cancer applications. So far we know that Targretin is the best available treatment for breast cancer in rats and we hope that we get the same good results for the human application. Andreas

To: Hippieslayer who wrote (15208)	2/17/1998 6:00:00 PM
From: bob smith	Respond to of 32384

> Bill Clinton telling you that your daughter is in safe in his hands. The unfortunate truth is that LGND will probably be stuck in a narrow trading range and will only move up substantially with the release of positive news.< That's about it! All this other price predicting BS is only speculation and hype. Bob